Elk Creek Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elk Creek Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,356	Closed	-$201K	–	133
2018 Q4	$201K	Sell	2,356 -2,979	-56%	-$283K	0.02%	133
2018 Q3	$517K	Hold	5,335	–	–	0.03%	131
2018 Q2	$503K	Sell	5,335 -256	-5%	-$22.4K	0.03%	136
2018 Q1	$453K	Buy	5,591 +817	+17%	+$70.1K	0.03%	138
2017 Q4	$426K	Buy	4,774 +1,616	+51%	+$141K	0.03%	140
2017 Q3	$294K	Buy	3,158 +77	+2%	+$6.8K	0.02%	145
2017 Q2	$280K	Hold	3,081	–	–	0.02%	148
2017 Q1	$270K	Buy	+3,081	New	+$274K	0.02%	147
2016 Q4	–	Sell	-3,305	Closed	-$306K	–	151
2016 Q3	$306K	Buy	3,305 +326	+11%	+$30.7K	0.02%	139
2016 Q2	$232K	Sell	2,979 -3,438	-54%	-$292K	0.02%	142
2016 Q1	$529K	Sell	6,417 -746	-10%	-$60.7K	0.04%	143
2015 Q4	$750K	Sell	7,163 -162	-2%	-$16.9K	0.05%	136
2015 Q3	$771K	Buy	7,325 +1,433	+24%	+$191K	0.06%	145
2015 Q2	$806K	Sell	5,892 -6,171	-51%	-$765K	0.07%	139
2015 Q1	$1.5M	Sell	12,063 -4,746	-28%	-$503K	0.16%	142
2014 Q4	$1.52M	Buy	+16,809	New	+$1.4M	0.2%	138

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Elk Creek Partners's BMRN Position: Q1 2019 in Review

Elk Creek Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 2,356 shares — an estimated $201K sold.

Elk Creek Partners first reported a position in BMRN in Q4 2014 and held it in 16 quarters. The position peaked at $1.52M in Q4 2014. 486 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

Elk Creek Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Elk Creek Partners sold 2,356 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $201K.
Elk Creek Partners first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 16 quarters.
Elk Creek Partners's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2014.
486 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Elk Creek Partners's 13F filing for Q1 2019, filed 10 May 2019.